Tofacitinib or adalimumab versus placebo: Patientreported outcomes from a phase 3 study of active rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 55, Issue 6, 2016, Pages 1031-1041

  Strand, Vibeke ^a   van Vollenhoven, Ronald F ^b   Lee, Eun Bong ^c   Fleischmann, Roy ^d   Zwillich, Samuel H ^e   Gruben, David ^e   Koncz, Tamas ^e   Wilkinson, Bethanie ^e   Wallenstein, Gene ^e  

^a Karolinska Institute ^*  (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Seoul National University   (South Korea)

^d METROPLEX CLINICAL RESEARCH CENTER   (United States)

^e PFIZER INC   (United States)

Author keywords

Janus kinase; Patient reported outcomes; Phase 3; Rheumatoid arthritis; Tofacitinib

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO; TOFACITINIB; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; GLOBAL ASSESSMENT OF FUNCTIONING; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOMES STUDY SLEEP; MUSCULOSKELETAL DISEASE ASSESSMENT; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT ASSESSMENT; PATIENT ASSESSMENT OF ARTHRITIS PAIN; PATIENT GLOBAL ASSESSMENT OF ARTHRITIS; PATIENT REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SHORT FORM 36; SOCIAL INTERACTION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; MIDDLE AGED; PATHOLOGY; PATIENT-REPORTED OUTCOME; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PIPERIDINES; PYRIMIDINES; PYRROLES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84974817790     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev442     Document Type: Article

References (34)

1. Kosinski M, Kujawski SC, Martin R et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231-40.
2. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121-45.
3. Matcham F, Scott IC, Rayner L et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:123-30.
4. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res 2010;62:640-6.
5. Wolfe F, Michaud K, Li T. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol 2006;33:1942-51.
6. Sokka T, Kautiainen H, Pincus T et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther 2010; 12:R42.
7. van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
8. Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
9. Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.
10. van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
11. Kremer J, Li ZG, Hall S et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253-61.
12. Lee EB, Fleischmann R, Hall S et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
13. Strand V, Rentz AM, Cifaldi MA et al. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol 2012;39:63-72.
14. Strand V, Burmester GR, Zerbini CA et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a Phase 3 trial. Arthritis Care Res 2015;67:475-83.
15. Strand V, Kremer J, Li ZG et al. Tofacitinib (CP-690,550) in combination with traditional disease-modifying antirheumatic drugs: patient-reported outcomes from a phase 3 study in patients with active rheumatoid arthritis and an inadequate response to disease-modifying anti-rheumatic drugs. Arthritis Rheum 2011;63:S1032-3.
16. Strand V, van der Heijde D, Zerbini CAF et al. ORAL SCAN: effects of the oral JAK inhibitor tofacitinib in combination with methotrexate on patient reported outcomes in a 24-month phase 3 trial of active rheumatoid arthritis. Arthritis Rheum 2013;65:S996. Abstract No. 2334 (abstract).
17. Alten R, Strand V, Fleischmann R et al. Effects of tofacitinib monotherapy versus methotrexate on patientreported outcomes in the 2-year Phase 3 ORAL Start trial in methotrexate-naïve patients with rheumatoid arthritis. Ann Rheum Dis 2014;73(Suppl 2):118-9. Abstract No. OP0152 (abstract).
18. Strand V, Kanik K, Connell CA et al. The effects of the oral JAK inhibitor CP-690,550 on patient reported outcomes in a phase 3 study of active rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl 3):88-9 (abstract).
19. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
20. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008;67:260-5.
21. Strand V, Boers M, Idzerda L et al. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011;38:1720-7.
22. Strand V, Scott DL, Emery P et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590-601.
23. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, eds. Measuring functioning and well-being. Durham, NC: Duke University Press, 1992, 235-9.
24. Ware JE, Kosinski M, Dewey JE. How to score version two of the SF-36 health survey. Lincoln, RI: QualityMetric Incorporated, 2000.
25. Strand V, Mease P, Burmester GR et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Res Ther 2009;11:R170.
26. Strand V, Smolen JS, van Vollenhoven RF et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011;70:996-1002.
27. Carr A, Hewlett S, Hughes R et al. Rheumatology outcomes: the patient's perspective. J Rheumatol 2003;30:880-3.
28. Uguz F, Akman C, Kucuksarac S, Tufekci O. Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci 2009;63:50-5.
29. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology 2013;52:2136-48.
30. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebocontrolled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
31. Bathon JM, Cohen SB. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road. Arthritis Rheum 2008;59:757-9.
32. Saag KG, Teng GG, Patkar NM et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
33. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease- modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
34. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.